Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1693
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17606441 | STABILIZATION AND PRESERVATION OF IN VITRO TRANSCRIPTION REACTIONS | Non-Final OA | President and Fellows of Harvard College |
| 17403592 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | Final Rejection | Genzyme Corporation |
| 17297586 | D-PSICOSE CRYSTAL AND PREPARATION METHOD THEREFOR | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 17625020 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18334457 | LIQUID COMPOSITION | Non-Final OA | Shin-Etsu Chemical Co., Ltd. |
| 18041785 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | Non-Final OA | EMORY UNIVERSITY |
| 17478016 | REVERSIBLE MODIFICATION OF NUCLEOTIDES | Non-Final OA | Illumina Cambridge Limited |
| 19003429 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | Non-Final OA | ARIBIO CO., LTD. |
| 17925180 | OLEOGEL AND OLEOPASTE COMPOSITIONS AND USES THEREOF | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 17995264 | PREPARATION FOR USE AS VASORELAXANT | Non-Final OA | Evonik Operations GmbH |
| 17594617 | PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | Final Rejection | 3M INNOVATIVE PROPERTIES COMPANY |
| 18237624 | NASAL SPRAY USING PENTOSAN POLYSULFATE AND MUCOPOLYSACCHARIDE POLYSULFATE FOR COVID-19 PREVENTION AND TREATMENT | Non-Final OA | Rensselaer Polytechnic Institute |
| 18045744 | COMPOSITIONS AND METHODS FOR PREDICTING THERAPEUTIC OUTCOME | Non-Final OA | Washington University |
| 18004271 | CONJUGATION OF PROTEINS TO POLYSACCHARIDES USING A PHOSPHATE BRIDGE | Final Rejection | Wisconsin Alumni Research Foundation |
| 18030186 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17298283 | USE OF GUAR DERIVATIVES FOR MICROORGANISMS GROWTH | Non-Final OA | RHODIA OPERATIONS |
| 17502665 | Dietary Supplements and Composition for Treating Cancer | Non-Final OA | The Trustees of Princeton University |
| 17275146 | METHOD FOR PRODUCTION OF A SWEETNER | Non-Final OA | SÜDZUCKER AG |
| 17621987 | LIQUID PHASE SEPARATION OF 2G SUGARS BY ADSORPTION ON A FAU ZEOLITE HAVING A SI/AL ATOMIC RATIO GREATER THAN 1.5 | Non-Final OA | IFP Energies nouvelles |
| 18438667 | Method and compositions for treating animal viral infections | Non-Final OA | PHOENIX BIOTECHNOLOGY, INC. |
| 17580129 | METHODS TO PREVENT, INHIBIT OR TREAT INTERVERTEBRAL DISC DEGENERATION | Non-Final OA | University of Iowa Research Foundation |
| 17617682 | RHAMNOSE-POLYSACCHARIDES | Non-Final OA | UNIVERSITY OF DUNDEE |
| 18166114 | SODIUM DEOXYCHOLATE BILE ACID AS ANTIBIOTIC CARRIER | Non-Final OA | The United States of America, as represented by the Secretary of Agriculture |
| 17927004 | FAST DISPERSIBLE PHARMACEUTICAL COMPOSITION COMPRISING CAPECITABINE | Non-Final OA | SHILPA MEDICARE LIMITED |
| 17431537 | ACETYLATION OF NATURAL FIBRES TO OBTAIN THE FIBROUS STRUCTURE | Final Rejection | CERDIA INTERNATIONAL GMBH |
| 18033160 | SPRAYABLE ANTIVIRAL FORMULATION | Non-Final OA | The University of Birmingham |
| 18377942 | RECRYSTALLIZATION METHOD FOR NMN PREPARATION | Non-Final OA | QINGDAO RESTORE BIOTECHNOLOGY CO., LTD. |
| 18021709 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Final Rejection | RISEN (SUZHOU) PHARMA TECH CO., LTD. |
| 18001614 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | Final Rejection | GLYCOMIMETICS, INC. |
| 18222106 | Soft Tissue Filler and Methods | Final Rejection | Carbon Medical Technologies, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy